Short‐term and long‐term outcomes of indigo naturalis treatment for inflammatory bowel disease

2019 ◽  
Vol 35 (3) ◽  
pp. 412-417 ◽  
Author(s):  
Yuichi Matsuno ◽  
Atsushi Hirano ◽  
Takehiro Torisu ◽  
Yasuharu Okamoto ◽  
Yuta Fuyuno ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Long Term Outcomes ◽  
Short Term ◽  
Indigo Naturalis ◽  
Inflammatory Bowel

Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes

2020 ◽  
Vol 26 (12) ◽  
pp. 1901-1908 ◽  
Author(s):  
Matthew Peverelle ◽  
Sarang Paleri ◽  
Jed Hughes ◽  
Peter De Cruz ◽  
Paul J Gow
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Liver Transplantation ◽  
Bowel Disease ◽  
Sclerosing Cholangitis ◽  
High Grade ◽  
Long Term Outcomes ◽  
Inflammatory Bowel ◽  
The Impact

Abstract Background The impact of inflammatory bowel disease (IBD) activity on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC) is unknown. We examined the impact of post-LT IBD activity on clinically significant outcomes. Methods One hundred twelve patients undergoing LT for PSC from 2 centers were studied for a median of 7 years. Patients were divided into 3 groups according to their IBD activity after LT: no IBD, mild IBD, and moderate to severe IBD. Patients were classified as having moderate to severe IBD if they met at least 1 of 3 criteria: (i) Mayo 2 or 3 colitis or Simple Endoscopic Score–Crohn’s Disease ≥7 on endoscopy; (ii) acute flare of IBD necessitating steroid rescue therapy; or (iii) post-LT colectomy for medically refractory IBD. Results Moderate to severe IBD at any time post-transplant was associated with a higher risk of Clostridium difficile infection (27% vs 8% mild IBD vs 8% no IBD; P = 0.02), colorectal cancer/high-grade dysplasia (21% vs 3% both groups; P = 0.004), post-LT colectomy (33% vs 3% vs 0%) and rPSC (64% vs 18% vs 20%; P < 0.001). Multivariate analysis revealed that moderate to severe IBD increased the risk of both rPSC (relative risk [RR], 8.80; 95% confidence interval [CI], 2.81–27.59; P < 0.001) and colorectal cancer/high-grade dysplasia (RR, 10.45; 95% CI, 3.55–22.74; P < 0.001). Conclusions Moderate to severe IBD at any time post-LT is associated with a higher risk of rPSC and colorectal neoplasia compared with mild IBD and no IBD. Patients with no IBD and mild IBD have similar post-LT outcomes. Future prospective studies are needed to determine if more intensive treatment of moderate to severe IBD improves long-term outcomes in patients undergoing LT for PSC.

Mo1893 Long-Term Outcomes After Primary Infliximab Treatment Failure in Patients With Inflammatory Bowel Disease

2016 ◽  
Vol 150 (4) ◽  
pp. S809
Author(s):  
Sine Buhl ◽  
Casper Steenholdt ◽  
Märta K. Borghede ◽  
Maria Rasmussen ◽  
Jorn Brynskov ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Treatment Failure ◽  
Bowel Disease ◽  
Infliximab Treatment ◽  
Long Term Outcomes ◽  
Inflammatory Bowel

Long-Term Outcomes of Proactive Versus Reactive Therapeutic Drug Monitoring for Optimizing Infliximab Therapy in Inflammatory Bowel Disease

2017 ◽  
Vol 152 (5) ◽  
pp. S381-S382
Author(s):  
Konstantinos Papamichail ◽  
Karen A. Chachu ◽  
Ravy K. Vajravelu ◽  
Byron P. Vaughn ◽  
Josephine Ni ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Infliximab Therapy ◽  
Therapeutic Drug ◽  
Long Term Outcomes ◽  
Inflammatory Bowel

Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

2020 ◽  
Vol 51 (9) ◽  
pp. 870-879 ◽  
Author(s):  
Iago Rodríguez-Lago ◽  
Jesús Castro-Poceiro ◽  
Agnès Fernández-Clotet ◽  
Francisco Mesonero ◽  
Antonio López-Sanromán ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Response ◽  
Bowel Disease ◽  
Short Term ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document